Skip to content
Select your cancer type
▼
  • ESCC
  • GC/GEJC
  • NSCLC
Indication:
▼
  • 1 L ESCC
  • 1 L GC/GEJC
  • 2 L ESCC
  • Non-Squamous NSCLC
  • Squamous NSCLC

Language

This site is inteded for health care proffesional.

Proven to extend mPFS, ORR and mDoR in patients with advanced and metastatic Squamous NSCLC

Key Efficacy Outcome: mPFS

  Etapidi demonstrated clinical benefit regardless of PD-L1 expression. 

Progression-free survival by independent review committee:
all in the ITT analysis set; final analysis data cut-off.

by subgroup for etapidi + chemotheraphy(PC) vs chemoteraphy only

by subgroup for etapidi + chemotheraphy (nPC) vs chemoteraphy only

Etapidi with chemotherapy significantly prolonged
median progression-free survival by 40%

Progression-free survival by independent review committee for arm A versus arm C

Key Efficacy Outcome: ORR & mDOR

Overall response rate was greater and DoR longer with Etapidi combined with chemotherapy vs chemotherapy alone

View safety in Squamous NSCLC

PFS, progression-free survival; PC, paclitaxel plus carboplatin; nPC, nab-paclitaxel plus carboplatin; PD-L1, programmed death-ligand 1; CI, confidence interval; HR, hazard ratio; ITT, intent-to-treat; CI=confidence interval, DoR=duration of response, HR=hazard ratio, IRC=independent review committee, mDoR=medium duration of response, nab-PC=nanoparticle albumin-bound paclitaxel plus carboplatin, NE=not evaluable, ORR=overall response rate, PC=paclitaxel plus carboplatin

Reference: 1. Wang et al. ESMO Open Volume 9, Issue 10, 2024 (final analysis of RATIONALE-307)